TY  - JOUR
UR  - https://doi.org/10.4193/Rhin23.278
SN  - 0300-0729
VL  - 62
SP  - 410
N1  - * Megosztott szerz?ség
IS  - 4
EP  - 420
A1  -  Kiricsi Ágnes
A1  -  Bella Zsolt
A1  -  Kraxner Helga
A1  -  Szalóki Tibor
A1  -  Fent Zoltán
A1  -  Liktor Balázs
A1  -  Huszka J.
A1  -  László P.
A1  -  Gobol D.
A1  -  Helfferich F.
A1  -  Vaska Z.
A1  -  Piski Zalán
A1  -  Juhász-Loisch L.
A1  -  Horváth B.
A1  -  Galántai D.
A1  -  Krisztin N.
A1  -  Tóth L.
A1  -  Bódi A.
A1  -  Matuz Mária
A1  -  Lujber László
A1  -  Hirschberg Andor
TI  - Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps: results from eight Hungarian centres with 12-month follow-up
Y1  - 2024///
ID  - publicatio34818
AV  - restricted
JF  - RHINOLOGY
N2  - Background: Research on the immune mechanism behind chronic rhinosinusitis (CRS) has revealed various new endotypes, leading to targeted therapies, especially for severe uncontrolled CRS. Biologics are novel therapeutic strategies providing targeted treatment for the difficult-to-treat recalcitrant CRSwNP patients. Dupilumab is a fully human-derived monoclonal antibody that binds to IL4R?, inhibiting the signalling of both IL-4 and IL-13. In Hungary, it is approved for the treatment of uncontrolled CRSwNP according to criteria based on the EPOS2020 and the Hungarian guidelines. Methodology: This study aimed to collect and evaluate real-world therapeutic data of CRSwNP patients treated with dupilumab. One hundred thirty-five patients from eight different referral centres have been enrolled in this study, who received dupilumab since 2020. All subjects were adult patients (>18 years) with uncontrolled CRSwNP. Baseline data collection included demographics, medical history, previous surgeries, related comorbidities, total endoscopic nasal polyp score (NPS), SNOT22, nasal congestion parameters measured with visual analogue scale (VAS) and nasal obstruction evaluation scale (NOSE), loss of smell score (LSS) and eosinophil count. 300 mg dupilumab was administered subcutaneously every second week. Follow up visits were performed after 6 and 12 months. Results: After 6 and 12 months of treatment significant improvement was detected in all clinical parameters. Safety was proved, no severe side effects occurred, and no rescue treatment was necessary. Conclusions: Our real-life findings show that continuous dupilumab treatment is effective and safe in daily clinical practice in CRSwNP and other type 2 comorbidities such as bronchial asthma and NERD.
ER  -